查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1544710

非侵入性产前检测市场、机会、成长动力、产业趋势分析与预测，2024-2032

Non-Invasive Prenatal Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 100 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于对早期和精确产前筛检的需求激增，非侵入性产前检测市场规模预计在 2024 年至 2032 年期间复合年增长率为 12.4%。

非侵入性产前检测 (NIPT) 是一种安全可靠的方法，可用于识别胎儿的遗传异常（例如唐氏症），同时对母亲和孩子的风险最小。随着人们对早期基因筛检优势的认识增强，对这些产品的需求也将增加。

新一代定序和生物资讯学的进步正在提高 NIPT 的准确性和效率，使其对准父母越来越有吸引力。随着新兴市场产前护理服务的普及和可支配收入的增加，产品采用率显着上升，因为越来越多的人能够负担得起并积极寻求先进的产前筛检服务。例如，2024年3月，BillionToOne在美国推出了一种新型产前基因测试“BabyPeek”

整个产业分为产品、技术、应用、最终用途和地区。

基于技术，PCR 领域的非侵入性产前检测市场规模预计到 2032 年将产生可观的收入，因为它在提高基因筛检的准确性和可靠性方面发挥关键作用。 PCR 技术能够熟练地放大和分析母体血液中发现的微量胎儿 DNA，从而以更高的灵敏度和特异性促进遗传异常的检测。

微缺失检测应用领域的 NIPT 市场预计将在 2024 年至 2032 年期间出现强劲的复合年增长率。微缺失涉及染色体小片段的缺失，这可能导致各种遗传性疾病。

亚太地区无创产前检测产业规模将在 2024 年至 2032 年间大幅成长。此外，基因检测的进步、更广泛的医疗服务、遗传性疾病盛行率的上升以及对及时、准确的产前护理的日益重视，都促进了该地区的市场发展。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 遗传性疾病发生率高
      • 技术进步
      • 对早期和非侵入性诊断的需求不断增长
      • 转向非侵入性测试
    • 产业陷阱与挑战
      • 道德考虑和测试成本
  • 成长潜力分析
  • 监管环境
  • 报销场景
  • 技术景观
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析
  • 流行病学情景
  • 差距分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 耗材和试剂
  • 仪器仪表
  • 服务

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

  • 主要趋势
  • NGS
  • 聚合酶炼式反应
  • 游离DNA
  • 其他技术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 三体检测
  • 微缺失检测
  • 性染色体非整倍体检测
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊断实验室
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Agilent Technologies, Inc.
  • BGI
  • Centogene N.V.
  • Eurofins LifeCodexx GmbH
  • F. Hoffmann-La Roche Ltd.
  • IGENOMIX
  • Illumina, Inc.
  • Labcorp
  • MedGenome Labs Ltd.
  • Myriad Women's Health, Inc.
  • Natera, Inc.
  • Pacific Biosciences
  • PerkinElmer Inc.
  • Progenity, Inc.
  • Quest Diagnostics, Inc
简介目录
Product Code: 10245

Non-invasive prenatal testing market size is set to record a 12.4% CAGR during 2024-2032 propelled by a surging demand for early and precise prenatal screening.

Non-invasive prenatal testing (NIPT) stands out as a secure and dependable method for identifying genetic anomalies in fetuses, such as Down syndrome, all while posing minimal risks to both mother and child. As awareness about the advantages of early genetic screening amplifies, the demand for these products will also rise.

Advancements in next-generation sequencing and bioinformatics are bolstering the accuracy and efficiency of NIPT, rendering it increasingly appealing to expectant parents. With enhanced access to prenatal care and rising disposable incomes in emerging markets, there is a notable uptick in product adoption, as more individuals can afford and are actively seeking advanced prenatal screening services. For example, in March 2024, BillionToOne launched 'BabyPeek', a novel prenatal genetic test, in the U.S.

The overall industry is divided into product, technology, application, end-use, and region.

Based on technology, the non-invasive prenatal testing market size from the PCR segment is expected to generate notable revenue by 2032 due to its pivotal role in enhancing the accuracy and reliability of genetic screening. PCR technology adeptly amplifies and analyzes minute quantities of fetal DNA found in maternal blood, facilitating the detection of genetic anomalies with heightened sensitivity and specificity.

NIPT market from the microdeletion detection application segment is projected to observe a robust CAGR during 2024 - 2032. This is owing to its ability to identify subtle genetic abnormalities that are not always detected by traditional screening methods. Microdeletions involve the loss of small segments of chromosomes, which can lead to various genetic disorders.

Asia Pacific non-invasive prenatal testing industry size will grow substantially between 2024 and 2032. This growth is fueled by heightened awareness of advanced prenatal screening technologies, increasing disposable incomes, and an evolving healthcare infrastructure. Moreover, advancements in genetic testing, broader access to healthcare, a rising prevalence of genetic disorders, and a growing emphasis on timely and accurate prenatal care bolster the region's market development.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 High incidence rate of genetic disorders
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Growing demand for early and non-invasive diagnosis
      • 3.2.1.4 Shift toward non-invasive testing
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Ethical considerations and cost of the test
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Technology landscape
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Epidemiology scenario
  • 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Consumables and reagents
  • 5.3 Instruments
  • 5.4 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 NGS
  • 6.3 PCR
  • 6.4 cfDNA
  • 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Trisomy detection
  • 7.3 Microdeletion detection
  • 7.4 Sex chromosome aneuploidy detection
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Agilent Technologies, Inc.
  • 10.2 BGI
  • 10.3 Centogene N.V.
  • 10.4 Eurofins LifeCodexx GmbH
  • 10.5 F. Hoffmann-La Roche Ltd.
  • 10.6 IGENOMIX
  • 10.7 Illumina, Inc.
  • 10.8 Labcorp
  • 10.9 MedGenome Labs Ltd.
  • 10.10 Myriad Women's Health, Inc.
  • 10.11 Natera, Inc.
  • 10.12 Pacific Biosciences
  • 10.13 PerkinElmer Inc.
  • 10.14 Progenity, Inc.
  • 10.15 Quest Diagnostics, Inc